Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLD: Mosunetuzumab Consolidation in Older DLBCL
NCT06828991Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Apr 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mosunetuzumab in diffuse large B-cell lymphoma (DLBCL) (2 arms). Primary endpoint: ctDNA clearance rate after mosunetuzumab treatment at 18 weeks. Started Sep 2025; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06828991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828991.